Dry Eye
Conditions
Brief summary
The goal of this clinical trial is to evaluate the effectiveness of Low Level Light Therapy (LLLT) in reducing the incidence or alleviating the severity of DED due to meibomian gland dysfunction in otherwise healthy patients undergoing cataract surgery. Participants will be randomly assigned in a 1:1 ratio to either a treatment group or a control group. The treatment group will receive LLLT one week before and one week after cataract surgery; the control group will not recieve LLLT at any time. Researchers will compare the treatment and the control group to see if patients receiving LLLT present with reduced signs and symptoms of ocular surface dysfunction with respect to the control group.
Interventions
DEVICELow Level Light Therapy
light-emitting diodes (LED), λ = 633 ± 10 nm; power of 100 mW/cm2, 15 minutes
Sponsors
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* healthy patients affected by senile cataract * patients scheduled for phacoemulsification and intraocular lens implantation
Exclusion criteria
* any other ocular comorbidity (e.g. glaucoma), * chronic instillation of eye drops of any type * previous ocular surgery or trauma to the addressed eye * previous cataract surgery in the controlateral eye, * active ocular infections * use of systemic drug with a known or suspected link to dry eye (e.g. diuretics, antidepressants, antihistamines, hormone replacement therapy) * autoimmune diseases (e.g. Sjögren syndrome) * intraoperative complications (e.g. capsular bag rupture requiring vitrectomy, suprachoroidal hemorrhage) * postoperative complications (e.g. endophthalmitis, vitritis)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Development or worsening of ocular surface abnormalities: tear meniscus height | One week (±2 days) after cataract surgery | Evaluation based on Oculus Keratograph 5 M (K5 M; Oculus GmbH, Wetzlar, Germany). Measurement expressed in millimeters. |
| Development or worsening of ocular surface abnormalities: non-invasive keratograph break up time (NIKBUT) FIRST | One week (±2 days) after cataract surgery | Evaluation based on slit lamp examination and Oculus Keratograph 5 M (K5 M; Oculus GmbH, Wetzlar, Germany). NIKBUT FIRST: interval time between the last complete blinking and the first distortion the 22 concentric rings reflected on the corneal surface. Measurement expressed in seconds. |
| Development or worsening of ocular surface abnormalities: non-invasive keratograph break up time (NIKBUT) AVG | One week (±2 days) after cataract surgery | Evaluation based on slit lamp examination and Oculus Keratograph 5 M (K5 M; Oculus GmbH, Wetzlar, Germany). NIKBUT AVG: average time of all tear film break-ups occurring in the measured period of up to 24.98 seconds (time limit set by the device's software). Measurement expressed in seconds. |
| Development or worsening of ocular surface abnormalities: non-invasive keratograph break up time (NIKBUT) CLASS | One week (±2 days) after cataract surgery | Evaluation based on slit lamp examination and Oculus Keratograph 5 M (K5 M; Oculus GmbH, Wetzlar, Germany). NIKBUT CLASS: classification incorporated in the instrument: class 0 \> 10 s (normal), class I 6 - 10 s, class II 3 - 6 s, class III \< 3 s.Measurement expressed in seconds. |
| Development or worsening of ocular surface abnormalities: bulbar redness | One week (±2 days) after cataract surgery | Evaluation based on Oculus Keratograph 5 M (K5 M; Oculus GmbH, Wetzlar, Germany). This parameter is expressed as as a ratio of vessels/free sclera and is automatically calculated by the instrument. |
| Development or worsening of ocular surface abnormalities: meibomian gland dropout | One week (±2 days) after cataract surgery | Evaluation based on Oculus Keratograph 5 M (K5 M; Oculus GmbH, Wetzlar, Germany). Dropout is calculated according to the JENVIS meibo scale. Grade 0= no dropout; grade 1= area of gland loss up to 33% of the total gland area; grade 2 = area of gland loss between 33 and 66%; grade 3 = area of gland loss of 67% or more |
| Development or worsening of ocular discomfort symptoms. | One week (±2 days) after cataract surgery | Evaluation based on the ocular surface disease index (OSDI) questionnaire. Normal OSDI: 0-12; a score of 13 or more is suggestive of dry eye disease (DED) Mild DED = 13 - 22; Moderate DED = 23-32; Severe DED \> 32 |
Countries
Italy
Outcome results
None listed